All News

Since its introduction in 1986, PSA screening has resulted in more than one million men being needlessly diagnosed and treated for prostate cancer, according to a study published online Aug. 31 in the Journal of the National Cancer Institute.

Men with coronary artery disease-induced congestive heart failure or heart attack who receive hormone therapy before or with radiation therapy for treatment of prostate cancer have an associated increased risk of death, according to researchers at Brigham & Women's Hospital-Dana Farber Cancer Institute, Boston.

Androgen deprivation therapy leads to an increased risk of bone fractures and other side effects of estrogen deficiency in men with prostate cancer, but those effects can be successfully treated with the use of an oral selective estrogen receptor modulator, suggest the results of a large, prospective, randomized tria presented at the AUA annual meeting in Chicago.

In a phase II study, about 40% of men with clinically localized, high-risk prostate cancer were free of biochemical recurrence at 18 months when treated with neoadjuvant docetaxel (Taxotere) and ketoconazole followed by surgical excision, according to research presented at the AUA annual meeting.